ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities), Step 3 was released for public comment on 16 June 2011. This guideline describes approaches to developing process and drug substance understanding, and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 – 3.2.S.2.6. It provides further clarification on the principles and concepts described in ICH guidelines on Pharmaceutical Development (Q8 R2), Quality Risk Management (Q9) and Pharmaceutical Quality System (Q10) as they pertain to the development and manufacture of drug substances. ICH guideline Q11 on development and manufacture of drug substances.
Are You Ready for an FDA Audit of Your Downstream Process?
Thursday, 27 Apr 2017 08.04
Meet PT Kalbio Global Medika – 2017 FOYA Honorable Mention Winner
Wednesday, 26 Apr 2017 09.04
Maximize Your Professional Development at These Signature Events
Tuesday, 25 Apr 2017 12.04